KalVista Reports Positive Phase II Data For Oral HAE Attack Therapy KVD900
Drug Appears Well Positioned Vs. Approved Therapies
Executive Summary
The company sees KVD900 as potentially “ideal” for patients using on-demand and prophylactic therapy, given the existing need to carry backup on-demand medications.
You may also be interested in...
Ionis’ HAE Opportunity Boosted By Positive Phase II Data
Positive topline Phase II data for Ionis’ antisense hereditary angioedema candidate has boosted the biotech’s chances of developing PKK-LRx as a treatment for the disease.
Finance Watch: SPAC Spree To Continue ‘For Foreseeable Future’
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.